FUNDAMENTALS · Fundamentals · FR Healthcare

Sanofi (SNY) Fundamentals 2026 — P/E 12.4x, Revenue Analysis | SniperIQ

Sanofi (SNY) is a FR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of

05.5B, trading at $43.88 on the NASDAQ. This SniperIQ fundamentals page covers Sanofi's valuation (P/E 12.4x, P/B 1.3x), profitability (net margin 16.0%), revenue (€46.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
05.5B
P/E (TTM)12.4x
Net Margin16.0%
Revenue (FY25)€46.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Sanofi's market cap?

Sanofi (SNY) has a market capitalization of approximately

05.5B, trading at $43.88 on the NASDAQ. Market cap moves with the live share price.

What is Sanofi's P/E ratio?

Sanofi's trailing twelve-month P/E ratio is 12.4x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Sanofi?

Sanofi runs a net profit margin of 16.0%, a gross margin of 71.9%, and an operating margin of 19.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Sanofi generate?

Sanofi reported revenue of €46.7B for fiscal year 2025, with net income of €7.8B and earnings per share (EPS) of 3.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Sanofi pay a dividend?

Sanofi offers a trailing dividend yield of about 5.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Sanofi financially healthy?

Sanofi carries a debt-to-equity ratio of 0.27x and a current ratio of 1.01x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Sanofi a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sanofi (SNY) the key facts are: market cap

05.5B, P/E 12.4x, revenue €46.7B, 52-week range 40.89-52.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Sanofi's full fundamentals live

Get Sanofi's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Sanofi Consumer Healthcare India (SANOFICONR) fundamentals · Medtronic (MDT) fundamentals · Genexine (095700) fundamentals · Jeil Pharma Holdings (002620) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons